DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award
About
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings. https://cdmrp. health. mil/pubs/press/2026/tbdrppreann.
The DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award (TDRA) is a federal research grant program designed to support product-driven development of therapeutics and diagnostics for tick-borne diseases, with particular focus on Lyme disease. This grant is ideal for researchers, biotech companies, and healthcare innovators working on early-stage therapeutic and diagnostic solutions that can meaningfully reduce disease burden and improve patient outcomes. The program prioritizes treatment-focused applications involving therapeutic evaluation studies that advance drug discovery and novel treatment approaches in preclinical development stages, as well as diagnosis-focused applications proposing innovative diagnostic methods readily implementable in clinical settings. If your organization is developing new approaches to treat or diagnose tick-borne diseases, this award provides an opportunity to secure federal funding for research that could transform patient care. The Tick-Borne Disease Research Program (TBDRP) supports high-impact research aligned with military health priorities, making it an excellent fit for academic institutions, private biotech firms, and medical device companies advancing solutions in this critical public health area. Applicants should visit the official DoD CDMRP website for complete eligibility requirements and detailed funding parameters specific to FY2026.
Funding Facts
● Applications openDeadline
October 22, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle—consult official announcement
Deadline
2026-10-22
Grant Type
federal
Application Cycle
Annual (FY2026 cycle with October 22, 2026 deadline)
Best For
Biotech companies, academic medical centers, research institutions, and diagnostic/pharmaceutical firms developing tick-borne disease therapeutics and diagnostics
Frequently Asked Questions
Who is eligible for DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award?
Specific eligibility criteria are not detailed in the available information. Interested applicants should consult the official DoD CDMRP announcement at https://cdmrp.health.mil/pubs/press/2026/tbdrppreann for comprehensive eligibility requirements, which may include institutional affiliation, research capacity, and compliance standards.
How much funding does DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award provide?
Funding amounts vary by cycle and are not specified in the current summary. Visit the official DoD CDMRP website for FY2026 funding details, including award ranges and budget caps applicable to this cycle.
How do I apply for DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award?
Applications are submitted through the DoD CDMRP portal. Visit https://cdmrp.health.mil/pubs/press/2026/tbdrppreann for the complete pre-announcement with submission guidelines, required forms, and detailed instructions. The application deadline is October 22, 2026.
What can DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award funding be used for?
Funding supports two focus areas: (1) Therapeutic research—therapeutic evaluation studies and early-stage drug/treatment discovery research aimed at advancing new therapeutic ideas in preclinical development; (2) Diagnostic research—diagnostic approach development designed for clinical integration. All work must target reducing burden of Lyme disease and/or other tick-borne diseases while improving patient care and quality of life.
Last updated: July 5, 2026